IPO
IPO filing, visualized

Medical 21, Inc.

S-1/A · Mar 20, 2026Filed

No price range yet · latest SEC filing Oct 23, 2026.

Pinch-zoom for details.

The offering

Price range
$10–$12
per share
Shares offered
2.27M
+341K over-allotment option
Raise at $11 midpoint
$25.0M
2,272,727 × $11, before fees

What the company does

Development-stage medical device company working on a synthetic graft (MAVERICS) for coronary artery bypass surgery.

Operating result

Fiscal year

Net result

Fiscal year

Things to weigh

  • Loss-making: net loss of $10.2M in FY2025.

The numbers

$FY2024FY2025YoY
Operating result(11.3M)(10.2M)+10.1%
Net result(11.4M)(10.2M)+10.0%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. We have incurred significant operating losses every year since our inception and have not generated any revenue
  2. Our financial performance will depend on the commercial success of our current product candidate and future products
  3. There is substantial doubt about our ability to continue as a going concern
  4. Even if this offering is successful, we will require additional capital to fund our operations, which may not be available on acceptable terms…
  5. We may encounter difficulties in managing our growth, which could negatively impact our operations
  6. Unstable market and economic conditions, including as a result of geopolitical events, may have serious adverse consequences on our business…

The filing's own risk-factor headings, shortened.

Strategy

  1. Scalability: Our finished MAVERICS grafts are not cultured, offering commercial-scale manufacturing
  2. Off-the-Shelf: Our grafts for CABG are shipped sterile and in final packaging
  3. Long-Term Shelf Stability
  4. Ease of Implant: Our product is easily implanted by the surgeon
  5. No Surgical Harvesting: Using our graft removes the need to harvest an autologous vessel from the patient, resulting in a faster procedure…
  6. Consistent Uniformity and Surgical Handling

The filing's own strategy headings, shortened.

Source: Medical 21, Inc.'s Form S-1/A, filed with the SEC on Mar 20, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10kdecoder.com